GLP-1 Coverage for 2027: Four Choices for Small and Mid-Sized Employers

Two business leaders talking at a small conference table over a laptop in a bright office

Key takeaways

  • GLP-1 drugs such as Wegovy and Zepbound are one of the biggest drivers of rising health plan costs heading into 2027 renewals.
  • In a 2026 Business Group on Health survey of large employers, 67% covered GLP-1s for weight management, and about 1 in 10 of those expect to stop in 2027.
  • Small and mid-sized employers with fully insured plans usually choose among the options their carrier offers, so the decision is often about riders and plan design.
  • There are four common approaches: cover with guardrails, cover for diabetes only, add a separate weight management program, or exclude with clear communication.
  • Whatever you choose, decide before renewal and tell employees early, especially anyone already taking one of these medications.

GLP-1 medications have become a regular part of renewal conversations across Maryland, DC and Virginia, and new pill versions are on the market. The good news is that you have real choices. The important thing is to make one on purpose, before your 2027 renewal, rather than letting the renewal make it for you.

Why this is on the table for 2027

GLP-1 drugs were first used for type 2 diabetes, and most health plans still cover them for that purpose. Coverage for weight loss is a separate decision. In a survey of large employers published by the Business Group on Health in May 2026, 67% covered GLP-1s for weight management, nearly 8 in 10 said the drugs are driving up their health care costs, and about 1 in 10 of those that cover them said they will likely stop in 2027.

Two newer developments matter too. The FDA approved an oral version of Wegovy in late 2025 and Eli Lilly’s pill, Foundayo, in April 2026. In the same survey, 87% of employers expected pills to increase overall demand, and only 9% expected prices to fall. Meanwhile, list prices have started to move. In March 2026, Lilly began selling Zepbound directly to employer health plans through independent program administrators at $449 for a typical monthly supply.

Why the decision looks different for a 40-person company

Most of the headlines come from large, self-funded employers that design their own pharmacy benefit. If your plan is fully insured, which is common for small and mid-sized employers in the DMV, coverage for weight loss drugs generally follows the plan design and riders your carrier offers. That narrows the menu, but it also simplifies the decision. If your plan is level-funded or self-funded, you have more flexibility, and the cost of each prescription shows up more directly in your own claims.

Either way, the first question is the same: what does your current plan do today? It is worth confirming, because a plan can already cover these drugs, or already exclude them, without anyone having made that choice on purpose.

Four ways employers are handling GLP-1 coverage

1. Cover them, with guardrails

Some employers keep weight loss coverage but add conditions. Common examples from the survey include confirming clinical eligibility with objective health measures, requiring participation in a weight management program, limiting prescribing to certain providers and covering only certain medications. Ask your carrier which of these options your plan can include.

2. Cover them for diabetes only

This keeps coverage for the use most plans already include and excludes coverage for weight loss alone. It controls cost, but employees who are prescribed a GLP-1 for weight management would pay the full price on their own, so it calls for clear communication.

3. Add a separate weight management program

Some employers pair drug coverage with, or replace it with, a structured program that includes coaching, nutrition support and medical oversight. Newer direct purchasing arrangements may also make it possible to offer the drugs outside the usual pharmacy benefit. Whether that works for you depends on how your plan is funded and administered.

4. Exclude them, and explain why

Not covering GLP-1s for weight loss is a legitimate choice, especially when it keeps the rest of the plan affordable for everyone. If you go this way, say so plainly in your enrollment materials, explain the reason in human terms and let employees know that their doctor can discuss other options, including manufacturer self-pay programs.

What to tell employees

Whatever you decide, the conversation matters as much as the decision. If you are changing coverage, give employees as much notice as you can, and think about anyone who is already taking one of these medications today. A sudden stop mid-treatment is hard on people, and a thoughtful transition goes a long way toward keeping trust. A simple explanation of what is covered, what is not and why will answer most of the questions HR would otherwise get one at a time.

Questions to bring to your renewal meeting

  • Does our current plan cover GLP-1 drugs for weight loss, for diabetes or both?
  • What riders or plan design options does our carrier offer for 2027?
  • What guardrails, such as clinical criteria or program participation, can be added?
  • How are these drugs affecting our renewal, and what would each option change?
  • If we change coverage, what happens for employees who are already on treatment?

Our employee benefits team can walk through these questions with you before your renewal. We would rather show you the real numbers from your own plan than guess at them.

Frequently Asked Questions

Do employers have to cover GLP-1 drugs for weight loss?
No federal law requires it. For a fully insured plan, coverage follows the plan design and riders your carrier offers, along with any state requirements, so the options available to you depend on your carrier and plan.

Do most health plans cover GLP-1 drugs for diabetes?
Most do. Coverage for type 2 diabetes is common and is usually treated separately from coverage for weight management.

What happens to employees already taking a GLP-1 if we stop covering it?
Coverage for weight loss would end when the plan change takes effect. Giving employees advance notice lets them talk with their doctor about next steps, which may include a manufacturer self-pay program or another treatment.

Will the new GLP-1 pills lower costs for employers?
It is too early to say. In the 2026 Business Group on Health survey, most employers expected pills to increase overall demand, and few expected prices to fall.

Related reading from Capitol Benefits

Sources: Business Group on Health 2026 GLP-1 employer survey (May 2026); BenefitsPRO, Eli Lilly employer access program for Zepbound (March 2026).

Ready when you are

Let's take a look at what you've got.

A real review of your current coverage. No deck, no pressure, and usually some money saved along the way.